What to know
Tuberculosis Cases and Percentages by Initial Drug Regimen: United States, 1993–2023
Year | Total cases1 | HRZE2 | RPT-MOX3 | Multi (4+) drug regimen4 | Less than 4 drug regimen5 | ||||
---|---|---|---|---|---|---|---|---|---|
No. | (%) | No. | (%) | No. | (%) | No. | (%) | ||
2023 | 9,334 | 7,714 | (82.6) | 29 | (0.3) | 1,087 | (11.6) | 504 | (5.4) |
2022 | 8,056 | 6,574 | (81.6) | 18 | (0.2) | 1,005 | (12.5) | 459 | (5.7) |
2021 | 7,590 | 6,327 | (83.4) | 1 | (0.0) | 804 | (10.6) | 458 | (6.0) |
2020 | 6,947 | 5,808 | (83.6) | -- | -- | 740 | (10.7) | 399 | (5.7) |
2019 | 8,659 | 7,173 | (82.8) | -- | -- | 1,014 | (11.7) | 472 | (5.5) |
2018 | 8,785 | 7,286 | (82.9) | -- | -- | 1,033 | (11.8) | 466 | (5.3) |
2017 | 8,885 | 7,448 | (83.8) | -- | -- | 926 | (10.4) | 511 | (5.8) |
2016 | 9,017 | 7,668 | (85.0) | -- | -- | 913 | (10.1) | 436 | (4.8) |
2015 | 9,315 | 7,953 | (85.4) | -- | -- | 859 | (9.2) | 503 | (5.4) |
2014 | 9,171 | 7,828 | (85.4) | -- | -- | 838 | (9.1) | 505 | (5.5) |
2013 | 9,313 | 7,875 | (84.6) | -- | -- | 889 | (9.5) | 549 | (5.9) |
2012 | 9,679 | 8,272 | (85.5) | -- | -- | 868 | (9.0) | 539 | (5.6) |
2011 | 10,213 | 8,704 | (85.2) | -- | -- | 824 | (8.1) | 685 | (6.7) |
2010 | 10,805 | 9,129 | (84.5) | -- | -- | 876 | (8.1) | 800 | (7.4) |
2009 | 11,220 | 9,464 | (84.3) | -- | -- | 872 | (7.8) | 884 | (7.9) |
2008 | 12,613 | 10,617 | (84.2) | -- | -- | 962 | (7.6) | 1,034 | (8.2) |
2007 | 12,958 | 10,862 | (83.8) | -- | -- | 845 | (6.5) | 1,251 | (9.7) |
2006 | 13,392 | 11,153 | (83.3) | -- | -- | 880 | (6.6) | 1,359 | (10.1) |
2005 | 13,753 | 11,510 | (83.7) | -- | -- | 689 | (5.0) | 1,554 | (11.3) |
2004 | 14,189 | 11,693 | (82.4) | -- | -- | 694 | (4.9) | 1,802 | (12.7) |
2003 | 14,474 | 11,772 | (81.3) | -- | -- | 683 | (4.7) | 2,019 | (13.9) |
2002 | 14,689 | 11,797 | (80.3) | -- | -- | 630 | (4.3) | 2,262 | (15.4) |
2001 | 15,530 | 12,398 | (79.8) | -- | -- | 606 | (3.9) | 2,526 | (16.3) |
2000 | 15,868 | 12,456 | (78.5) | -- | -- | 670 | (4.2) | 2,742 | (17.3) |
1999 | 16,940 | 13,018 | (76.8) | -- | -- | 792 | (4.7) | 3,130 | (18.5) |
1998 | 17,724 | 13,164 | (74.3) | -- | -- | 761 | (4.3) | 3,799 | (21.4) |
1997 | 19,061 | 13,712 | (71.9) | -- | -- | 828 | (4.3) | 4,521 | (23.7) |
1996 | 20,424 | 13,750 | (67.3) | -- | -- | 894 | (4.4) | 5,780 | (28.3) |
1995 | 21,849 | 13,703 | (62.7) | -- | -- | 1,058 | (4.8) | 7,088 | (32.4) |
1994 | 23,196 | 12,924 | (55.7) | -- | -- | 1,287 | (5.5) | 8,985 | (38.7) |
1993 | 23,961 | 9,663 | (40.3) | -- | -- | 1,184 | (4.9) | 13,114 | (54.7) |
1Persons alive at diagnosis with initial drug regimen information.
2H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol.
3Daily 4-month regimen with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, first recommended by CDC in 2022.
4A drug regimen with at least four drugs, other than HRZE and RPT-MOX.
5Includes some recommended multi-drug regimens for drug-resistant TB as well as persons who were not prescribed any drugs.
Note
Data for all years are updated through July 17, 2024.
Double dashes (--) indicate that data are not available.